GSK stock heads into the open after a 4.6% jump on analyst upgrade

At the close on September 15, 2026, GSK stock traded around 1,858.5 pence in London, up about 4.6 percent over the prior close, as analyst upgrades and a new oncology deal supported the shares. The move left GSK stock still below raised price targets and the FTSE 100 lower on the day.

GSK stock closed near 1,858.5 pence in London trading on September 15, 2026, representing a gain of about 4.6 percent over the prior session on the London Stock Exchange.

September 15, 2026 in numbers

GSK plc (ISIN GB0009252882) saw its shares trade around 1,858.5 pence on the London Stock Exchange on September 15, 2026, compared with a prior close of 1,854.5 pence on September 14, 2026, implying a rise of roughly 4.6 percent over that earlier level.

According to market data summaries, the intraday trading range for GSK on September 15, 2026 ran from about 1,789.5 pence at the low to 1,861.5 pence at the high, keeping the close within that band and below recent 52-week highs for the shares.

In the broader market backdrop, the FTSE 100 index closed lower on September 15, 2026, with reports noting that the blue-chip benchmark declined around 0.6 percent as higher oil prices pushed bond yields up and weighed on UK equities, contrasting with the positive move in GSK stock that day as the shares outperformed the home index.

Analyst calls and oncology deal support today

The strong session for GSK on September 15, 2026 was linked to a combination of analyst upgrades and pipeline news. As MarketBeat reported on September 15, 2026, Berenberg Bank raised its recommendation on GSK to a buy rating and lifted its price target to 2,200 pence, framing a more constructive growth outlook for the company.

Separately, a session wrap by Ad-hoc-news highlighted that investors were also reacting to a new blood cancer drug deal worth up to 750 million USD, adding to confidence in GSK's oncology pipeline and helping drive the shares higher.

Another commentary from Seeking Alpha noted that Berenberg's raised price objective of 22 pounds implied about a 19 percent upside versus the closing price on September 14, 2026, underscoring the scale of potential re-rating that some analysts now see in the stock.

Heading into the open on September 16, 2026, these recent analyst actions and deal announcements remain the key reference points for GSK, with investors watching how the shares trade against the backdrop of a FTSE 100 that recently closed lower and ongoing discussions about UK bond yields and sector valuations.